Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906276 | 0.89 | RECQL (0.51) | RECQLMAPTKAT2BMAPK1PKM | |
| SCHEMBL2144702 | 0.88 | HCAR3 (0.51) | HCAR3MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2144699 | 0.88 | HCAR3 (0.51) | HCAR3MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20128511 | 0.83 | KDM4E (0.52) | HCAR3MAPTKDM4EMAPK1PKM | |
| SCHEMBL2144713 | 0.83 | HCAR3 (0.45) | HCAR3MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL26324521 | 0.81 | HCAR3 (0.63) | HCAR3MAPTKDM4EKAT2BMAPK1 | |
| SCHEMBL29670495 | 0.81 | ALDH1A1 (0.62) | HCAR3MAPTKDM4ETDP1MAPK1 | |
| SCHEMBL420259 | 0.81 | ALDH1A1 (0.62) | HCAR3MAPTKDM4ETDP1MAPK1 | |
| SCHEMBL15206115 | 0.81 | APEX1 (0.61) | HCAR3MAPTKDM4EMAPK1PKM | |
| SCHEMBL25056997 | 0.81 | GAA (0.67) | MAPTCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893066-B2 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2276748-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126123-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | SCD, SCD5, FASN | RECQL 3999/4885HCAR3 366/4885MAPT 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.